Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis

Analysis showed cumulative cost savings from Butec introduction alone was £0.7 million and predicts if all generic buprenorphine entered the market at the same time with Butec, a £1.2 million saving could have been achieved; meaning approx. £0.5 million savings was lost.